Does Medicare Cover Wegovy in 2026?

The CMS Medicare GLP-1 Bridge is a federal CMS demonstration, live July 1, 2026 through December 31, 2027, that gives eligible Part D enrollees a flat $50/month copay for Wegovy (injection and oral tablet), Foundayo (orforglipron), and Zepbound KwikPen. Eligibility: BMI of 35 or higher, or 30+ with a qualifying comorbidity, or 27+ with prediabetes or prior cardiovascular disease. Unlike the older CVD pathway, no ASCVD documentation is required.

Two practical things to know. First, participating Part D plans opt in - check your plan portal for Wegovy at the Bridge tier, and file a formulary exception through your prescriber if it is missing. Second, Bridge claims run on their own processor (BIN 028918 / PCN MEDDGLP1BR), not your normal Part D pathway - if the pharmacy submits the standard way, it auto-rejects and looks like a denial. Asking the pharmacist to rebill under the Bridge BIN/PCN resolves most of these.

Full program detail, including the "BALANCE Model" name confusion from early coverage: Medicare GLP-1 Bridge explained.

The Medicare Modernization Act of 2003, which created Part D, explicitly excluded from coverage "agents when used for anorexia, weight loss, or weight gain." That language is still on the books in July 2026. There have been multiple legislative efforts (notably the Treat and Reduce Obesity Act, TROA) to repeal the exclusion, but none have passed.

The 2024 cardiovascular expansion did not change the underlying statute. Instead, the FDA expanded Wegovy's label to include cardiovascular risk reduction, and CMS clarified that Part D plans can cover Wegovy for that indication - because it's no longer being used for weight loss alone.

The Medicare GLP-1 Bridge doesn't repeal the statute either - it is a CMS demonstration structured to reach weight-management patients despite the exclusion. If the Bridge lapses after December 31, 2027 without a successor program or a statutory fix, the pre-Bridge rules described on this page become the operative ones again.

The FDA label requires "established cardiovascular disease" in adults with overweight or obesity. In practice this means one of:

• Prior myocardial infarction (heart attack)
• Prior ischemic stroke
• Established coronary artery disease (e.g. prior catheterization showing stenosis)
• Prior peripheral arterial disease with documented vascular involvement
• Prior coronary or peripheral revascularization (stent, bypass, angioplasty)

What does NOT qualify on its own: hypertension, high cholesterol, family history of heart disease, prediabetes, or high CVD risk score without documented disease. Your prescriber needs the ICD-10 code for the qualifying condition on your chart before running the prior auth.

NovoCare's self-pay reference price is the cheapest legitimate path for Medicare patients who don't meet the CVD indication. Unlike the Wegovy Savings Card, NovoCare self-pay is NOT a copay-assistance program - it's a direct-to-patient pricing tier from Novo Nordisk that Medicare beneficiaries can access. As of July 2026, the reference price is approximately $349/month.

Apply at novocare.com.

Not for Medicare-access reasons - that gap closed on July 1, 2026. The Medicare GLP-1 Bridge covers both Wegovy and Zepbound KwikPen (the pre-filled pen; single-dose vials are excluded) at the same flat $50/month, so switching drugs no longer changes your Medicare access. Choose based on efficacy, tolerability, and availability instead. Outside the Bridge, the CVD pathway remains Wegovy-only: Zepbound has no analogous cardiovascular label expansion as of July 2026, and the Zepbound Savings Card is excluded for Medicare patients by the same federal anti-kickback rules.

If your plan hasn't added Zepbound at the Bridge tier, Medicare patients can still pay cash via Eli Lilly's LillyDirect self-pay vials (around $299/month for 2.5 mg, $399/month for 5 mg), which is not a copay-assistance program and is open to Medicare beneficiaries. Read more at How to Get Zepbound Without Insurance.